Related Experiment Videos
Drugs and steatohepatitis
1Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia. geoff_farrell@wmi.usyd.edu.au
Seminars in Liver Disease
|May 23, 2002
Summary
Drug-induced steatohepatitis, though uncommon, offers insights into metabolic nonalcoholic steatohepatitis (NASH) mechanisms. Early recognition of drug hepatotoxicity is vital for preventing severe liver disease progression.
Area of Science:
- Hepatology
- Toxicology
- Metabolic Syndrome
Background:
- Nonalcoholic steatohepatitis (NASH) is commonly linked to metabolic factors like insulin resistance, type 2 diabetes, obesity, and hypertriglyceridemia.
- Drug-induced liver injury is an infrequent cause of steatohepatitis, with the term drug-induced steatohepatitis reserved for direct drug toxicity.
- Some drug associations may be coincidental, as NASH is prevalent in metabolic syndrome, while others, like corticosteroids and tamoxifen, can exacerbate underlying metabolic issues.
Purpose of the Study:
- To explore the role of drugs and toxins in causing steatohepatitis.
- To understand the mechanisms of drug-induced steatohepatitis and its relationship to metabolic NASH.
- To highlight the clinical implications of drug-induced steatohepatitis, including potential progression after drug cessation.
Main Methods:
- Review of literature on drug-induced liver disease and nonalcoholic steatohepatitis.
- Analysis of proposed mechanisms involving mitochondrial injury, impaired fatty acid oxidation, and oxidative stress.
- Examination of clinical features, including prolonged therapy, drug accumulation, genetic factors (e.g., CYP2D6 polymorphism), and post-discontinuation progression.
Main Results:
- Certain drugs (corticosteroids, tamoxifen, estrogens, methotrexate) can precipitate or worsen NASH, particularly in predisposed individuals.
- Drug-induced steatohepatitis often involves prolonged therapy (>6 months) and potential drug accumulation.
- The toxic mechanism frequently involves mitochondrial dysfunction, leading to steatosis and cellular damage via reactive oxygen species and ATP depletion.
Conclusions:
- Drug-induced steatohepatitis provides valuable insights into the pathogenesis of metabolic NASH.
- Early identification of drug-induced hepatotoxicity is critical for timely intervention and improved patient outcomes.
- Some cases of drug-induced steatohepatitis may progress even after the causative agent is removed, underscoring the need for vigilant monitoring.